Nutriband Inc. CEO Temporarily Steps Down to Pursue Irish Presidency, Company Focuses on AVERSA Fentanyl Development

Nutriband Inc. (NASDAQ: NTRB) has announced a significant leadership change as CEO Gareth Sheridan steps aside for three months to pursue a candidacy in the upcoming Irish Presidential election. During Sheridan's absence, Co-Founder and Chairman Serguei Melnik will assume the role of CEO, bringing his extensive experience in corporate strategy and capital markets to guide the company. This transition comes at a critical time as Nutriband advances towards its 2026 NDA filing target for its innovative AVERSA Fentanyl abuse-deterrent opioid patch.

The AVERSA Fentanyl patch represents a groundbreaking advancement in pain management, designed to deter misuse and accidental exposure to fentanyl, a potent opioid with high abuse potential. The FDA has recently granted a meeting request for AVERSA Fentanyl, underscoring the product's significance in addressing the opioid crisis. With patents protecting the technology in 46 countries, Nutriband is poised to expand its availability to major global medical markets, projecting peak U.S. sales between $80 million and $200 million.

Sheridan expressed confidence in the leadership team's ability to maintain momentum during his temporary departure, highlighting the company's commitment to advancing AVERSA Fentanyl and other transdermal pharmaceutical products. For more information on Nutriband's developments, visit https://ibn.fm/YstUq.

This leadership transition and the progress on AVERSA Fentanyl underscore Nutriband's strategic positioning in the pharmaceutical industry, with potential implications for public health and the company's growth trajectory. The temporary change in leadership reflects the company's adaptability and the strength of its executive team, ensuring continuity in its mission to develop innovative, abuse-deterrent pharmaceutical products.